Source comparison
The Visceral vs Subcutaneous Mechanism That Shapes Timeline
Tesamorelin's selectivity for visceral adipose tissue isn't random. It reflects receptor density and metabolic activity differences between fat depots. Visceral fat contains higher concentrations of beta-adrenergic receptors (beta-1, beta-2, beta-3) that respo
This comparison does not assign a generated winner or score.
- Tesamorelin's selectivity for visceral adipose tissue isn't random. It reflects receptor density and metabolic activity differences between fat depots. Visceral fat contains higher concentrations of beta-adrenergic receptors (beta-1, beta-2, beta-3) that respond to catecholamine signaling triggered by growth hormone pulses. When GH binds to hepatic receptors, it stimulates IGF-1 production, which in turn activates hormone-sensitive lipase (HSL). The enzyme that breaks down triglycerides stored in adipocytes into free fatty acids and glycerol for oxidation.
- Subcutaneous fat has lower beta-receptor density and higher alpha-2 adrenergic receptor expression, which actively inhibits lipolysis. This is why tesamorelin produces 15–20% VAT reduction while subcutaneous fat drops by only 3–5% across the same timeframe. The timeline you experience depends entirely on which fat depot you're tracking. If you're measuring waist circumference or getting DEXA scans, changes appear at 12–16 weeks. If you're relying on mirror checks or total body weight, you'll see minimal movement until month five or six. If at all.
- Our team has found that patients who understand this mechanism upfront stay compliant longer. The compound is doing exactly what it's designed to do. It's just not designed to create visible six-pack definition in eight weeks.